Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice
- PMID: 33347498
- PMCID: PMC7751847
- DOI: 10.1371/journal.ppat.1009167
Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice
Abstract
[This corrects the article DOI: 10.1371/journal.ppat.1008477.].
Erratum for
-
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.PLoS Pathog. 2020 Apr 6;16(4):e1008477. doi: 10.1371/journal.ppat.1008477. eCollection 2020 Apr. PLoS Pathog. 2020. PMID: 32251475 Free PMC article.
Similar articles
-
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.PLoS Pathog. 2020 Apr 6;16(4):e1008477. doi: 10.1371/journal.ppat.1008477. eCollection 2020 Apr. PLoS Pathog. 2020. PMID: 32251475 Free PMC article.
-
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.PLoS Pathog. 2016 Aug 25;12(8):e1005745. doi: 10.1371/journal.ppat.1005745. eCollection 2016 Aug. PLoS Pathog. 2016. PMID: 27561082 Free PMC article.
-
Correction: HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.PLoS Pathog. 2017 Sep 7;13(9):e1006606. doi: 10.1371/journal.ppat.1006606. eCollection 2017 Sep. PLoS Pathog. 2017. PMID: 28880964 Free PMC article.
-
Modeling EBV infection and pathogenesis in new-generation humanized mice.Exp Mol Med. 2015 Jan 23;47(1):e135. doi: 10.1038/emm.2014.88. Exp Mol Med. 2015. PMID: 25613732 Free PMC article. Review.
-
Humanized mouse models of epstein-barr virus infection and associated diseases.Pathogens. 2013 Mar 14;2(1):153-76. doi: 10.3390/pathogens2010153. Pathogens. 2013. PMID: 25436886 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources